Janney Montgomery Scott assumed coverage on shares of bluebird bio (NASDAQ:BLUE) in a report issued on Wednesday, The Fly reports. The brokerage set a “neutral” rating on the biotechnology company’s stock.
Other equities analysts have also issued reports about the company. BMO Capital Markets set a $215.00 target price on bluebird bio and gave the company a “buy” rating in a report on Monday, December 11th. Jefferies Group raised bluebird bio from a “hold” rating to a “buy” rating and upped their target price for the company from $130.00 to $211.00 in a report on Monday, December 11th. Canaccord Genuity started coverage on bluebird bio in a report on Tuesday, December 5th. They issued a “buy” rating and a $202.00 target price for the company. Maxim Group upped their target price on bluebird bio from $170.00 to $200.00 and gave the company a “buy” rating in a report on Thursday, November 30th. Finally, SunTrust Banks upped their target price on bluebird bio to $223.00 and gave the company a “buy” rating in a report on Tuesday, December 12th. Three research analysts have rated the stock with a sell rating, nine have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $187.60.
bluebird bio (BLUE) opened at $223.35 on Wednesday. The stock has a market capitalization of $11,648.66, a P/E ratio of -29.16 and a beta of 2.06. bluebird bio has a twelve month low of $74.45 and a twelve month high of $236.17.
In other news, CEO Nick Leschly sold 5,435 shares of the firm’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $173.38, for a total value of $942,320.30. Following the completion of the transaction, the chief executive officer now directly owns 171,009 shares of the company’s stock, valued at $29,649,540.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Susanna Gatti High sold 17,262 shares of the firm’s stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $195.91, for a total value of $3,381,798.42. Following the completion of the transaction, the chief operating officer now directly owns 28,512 shares of the company’s stock, valued at $5,585,785.92. The disclosure for this sale can be found here. Over the last three months, insiders have sold 64,598 shares of company stock valued at $12,370,309. 3.90% of the stock is owned by corporate insiders.
Several institutional investors have recently bought and sold shares of BLUE. Two Sigma Advisers LP boosted its holdings in shares of bluebird bio by 3,004.0% in the fourth quarter. Two Sigma Advisers LP now owns 462,500 shares of the biotechnology company’s stock worth $82,371,000 after acquiring an additional 447,600 shares during the period. Redmile Group LLC purchased a new stake in shares of bluebird bio in the fourth quarter worth $46,270,000. Eagle Asset Management Inc. purchased a new stake in shares of bluebird bio in the third quarter worth $29,539,000. BlackRock Inc. raised its position in shares of bluebird bio by 6.4% in the fourth quarter. BlackRock Inc. now owns 3,831,371 shares of the biotechnology company’s stock worth $682,366,000 after buying an additional 231,697 shares in the last quarter. Finally, Franklin Resources Inc. raised its position in shares of bluebird bio by 41.3% in the fourth quarter. Franklin Resources Inc. now owns 686,900 shares of the biotechnology company’s stock worth $122,337,000 after buying an additional 200,900 shares in the last quarter.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.